Compliance failures are no longer theoretical
Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH
Without continued treatment or significant lifestyle changes, the appetite suppression effect ends when the medication does
The one clear fact was that patients with duodenal ulcers gave an exaggerated secretory response to histamine, the basis of a diagnostic test' (Black)
Personalization of Treatment to BMI and ORC Patient heterogeneity, including metabolically obese normal weight (MONW) individuals, patients with severe obesity (BMI 40), and sarcopenic elderly populations poses challenges for standardized interventions
Semaglutide robustly reduces appetite, promotes satiety, and significantly decreases body weight and glycemic parameters in both obese/overweight individuals and those with type 2 diabetes